Reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV) by SARS-CoV-2 in non-hospitalised HIV-infected patients

Lambarey, Humaira; Blumenthal, Melissa J.; Chetram, Abeen; Joyimbana, Wendy; Jennings, Lauren; Orrell, Catherine; Schäfer, Georgia

doi:10.1016/j.ebiom.2024.104986

Cited by 4 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As already described for other viral co-infections, SARS-CoV-2 can produce the transition of HHV8 from the latent phase to the lytic replication phase by stimulating the release of pro-inflammatory cytokines, leading to severe disease and death [ 32 , 33 , 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Unusual Localization of AIDS-Related Kaposi’s Sarcoma in a Heterosexual Male during the COVID-19 Pandemic: A Case Report

Arbune,

Padurariu-Covit,

Tiutiuca

et al. 2024

TropicalMed

View full text Add to dashboard Cite

Kaposi’s sarcoma is an AIDS-defining illness and remains the most frequent tumor arising in HIV-infected patients with multifactorial etiology. We present a case of a 30-year-old Caucasian male with an 18-year history of HIV infection. The patient was presented with a one-week history of fever, non-productive cough, and skin lesions. There was an associated weakness and weight loss in a duration of 6 months. Clinical examination showed fever, generalized lymphadenopathy, lower limb edema, ascites, and violaceous cutaneous eruption comprising patches, plaques, and nodules. He also had a red nodule on the left conjunctiva, as well as on his oral mucosa. His CD4+ count was below 10/mm3 and ARN-HIV viral load was above 100,000 c/mL, in relation to the antiretroviral failure after five drug regimens. The role of co-infections in oncogenesis and the course of Kaposi’s sarcoma were considered in recent studies. Delayed diagnosis of Kaposi’s sarcoma in the present case resulted in a negative impact for this patient during the COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Unusual Localization of AIDS-Related Kaposi’s Sarcoma in a Heterosexual Male during the COVID-19 Pandemic: A Case Report

Arbune,

Padurariu-Covit,

Tiutiuca

et al. 2024

TropicalMed

View full text Add to dashboard Cite

show abstract

“…Kaposi sarcoma-associated herpes virus (KSHV) is the etiological agent for all types of KS. KSHV is highly prevalent in some parts of the world such as Sub-Saharan Africa (SSA), where seroprevalence rates are above 50% in the adult populations of most countries [ 4 ], and has a low seroprevalence in most developed countries with reported seroprevalence rates below 10% [ 5 ]. This partly explains the high incidence and prevalence of KS in many SSA countries compared to developed countries [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Association between KSHV-Specific Humoral and T Cell Responses with Recurrence of HIV-Associated Kaposi Sarcoma

Mukasine,

Mulundu,

Kawimbe

et al. 2024

TropicalMed

View full text Add to dashboard Cite

Kaposi sarcoma (KS) is an AIDS-defining angio-proliferative malignancy, with the Kaposi sarcoma-associated herpes virus (KSHV) as its etiologic agent. Upon treatment with chemotherapy, a proportion of HIV-associated KS patients experience disease recurrence within a few months of completing treatment. We aimed at determining whether KSHV-specific adaptive immune responses were associated with KS recurrence upon complete remission. We conducted a prospective cohort study. The primary outcome was the recurrence of HIV-associated KS. An immunofluorescence assay was used to determine anti-KSHV antibodies, an enzyme-linked immunospot was conducted for T cell responses, PCR was carried out to determine KSHV status, and flow cytometry was used for CD4 counting and immunophenotyping. KSHV detection in PBMCs was high and not associated with KS recurrence-free survival (p = 0.29). Anti-KSHV antibody titers were high and not associated with recurrence-free survival (p = 0.63). KSHV-specific T cell responses dropped from baseline levels among individuals with recurrence, but the drop was not statistically significant. Individuals experiencing KS recurrence had a significantly higher proportion of T cell subsets expressing PD1, while those with sustained remission had a significant increase in CD4 T cell counts from baseline levels during the follow-up period (p = 0.02). Anti-KSHV antibodies are not a good correlate of protection from KS recurrence. T cells in individuals experiencing KS recurrence hadhigh PD1 expression, while an increase in CD4 counts was associated with sustained KS remission.

show abstract

Analysis of HHV-8/HIV-1 co-dynamics model with latency

Elaiw,

Almohaimeed,

Hobiny

2024

Eur. Phys. J. Plus

View full text Add to dashboard Cite

Reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV) by SARS-CoV-2 in non-hospitalised HIV-infected patients

Cited by 4 publications

References 49 publications

Unusual Localization of AIDS-Related Kaposi’s Sarcoma in a Heterosexual Male during the COVID-19 Pandemic: A Case Report

Unusual Localization of AIDS-Related Kaposi’s Sarcoma in a Heterosexual Male during the COVID-19 Pandemic: A Case Report

Association between KSHV-Specific Humoral and T Cell Responses with Recurrence of HIV-Associated Kaposi Sarcoma

Analysis of HHV-8/HIV-1 co-dynamics model with latency

Contact Info

Product

Resources

About